.
Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Pfizer w...
Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high...
Of the 129 children enrolled in the trial from across Australia with high-risk and relapsed cancers, 67% were provided with personalised treatment plans aimed at killing their unique cancer cells. For...
In a world first, Melbourne scientists have discovered a new type of anti-cancer drug that can put cancer cells into a permanent sleep, without the harmful side-effects caused by conventional cancer t...
Cancer Therapeutics CRC (CTx), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce two...
Mr Brett Carter will succeed Dr Warwick Tong who has led CTx for the past 6 years and who will continue to provide services to the organisation in an advisory capacity. These changes reflect a transit...